We picked Adamas Pharmaceuticals (ADMS) stock in our portfolio last year (see initiation article with full details). We reiterated Buy on the stock in a premium service post last month. We are revisiting this company ahead of the August 24 PDUFA date for ADS-5102 in the treatment of levodopa-induced dyskinesia, LID in Parkinson’s disease, PD.
